Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder

International Journal of Neuropsychopharmacology

Volumn 16, Issue 1, 2013, Pages 1-11

  Michelson, David ^a   Hargreaves, Richard ^a   Alexander, Robert ^a   Ceesay, Paulette ^a   Hietala, Jarmo ^b   Lines, Christopher ^a   Reines, Scott ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Generalized anxiety disorder; lorazepam; neurokinin 1 receptors substance P; randomized controlled trial

Indexed keywords

L 759274; LORAZEPAM; NEUROKININ 1 RECEPTOR;

ADULT; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SOMNOLENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LORAZEPAM; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, NEUROKININ-1; TREATMENT OUTCOME;

EID: 84871485341     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000065     Document Type: Article

References (33)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
2. Baldwin DS, Ajel KI, Garner M (2010). Pharmacological treatment of generalized anxiety disorder. Current Top Behavioral Neuroscience 2, 453-467.
3. Bergstrom M, Hargreaves R, Burns D, Goldberg M, et al. (2004). Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biological Psychiatry 55, 1007-1012.
4. Carson R, Channing M, Blasberg R, Dunn B, et al. (1993). Comparison of bolus and infusion methods for receptor quantitation : application to [18F]cyclofoxy and positron emission tomography. Journal of Cerebral Blood Flow and Metabolism 13, 24-42.
5. Culman J, Unger T (1995). Central tachykinins: mediators of defense reaction and stress reactions. Canadian Journal of Physiology and Pharmacology 73, 885-891.
6. Davidson JR (2009). First-line pharmacotherapy approaches for generalized anxiety disorder. Journal of Clinical Psychiatry 70(Suppl. 2), 25-31.
7. Ebner K, Sartori SB, Singewald N (2009). Tachykinin receptors as therapeutic targets in stress-related disorders. Current Pharmaceutical Design 15, 1647-1674.
8. Frank R, Hargreaves R (2003). Clinical biomarkers in drug discovery and development. Nature Reviews in Drug Discovery 2, 566-580.
9. Furmark T, Appel L, Michelgard A, Wahlstedt K, et al. (2005). Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biological Psychiatry 58, 132-142.
10. Gail M, Simon R (1985). Testing for qualitative interaction between effects and patient subsets. Biometrics 41, 361-372.
11. Guy W (ed.) (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare.
12. Hamilton M (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 32, 50-55.
13. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62.
14. Hargreaves R (2002). Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. Journal of Clinical Psychiatry 63(Suppl. 11), 18-24.
15. Hargreaves R (2008). The role of molecular imaging in drug discovery and development. Clinical Pharmacology and Therapeutics 83, 1-5.
16. Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, et al. (2006). Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14, 354-360.
17. Hietala J, Nyman MJ, Eskola O, Laakso A, et al. (2005). Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Moleular Imaging and Biology 7, 262-272.
18. Keller M, Montgomery S, Ball W, Morrison M, et al. (2006). Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biological Psychiatry 59, 216-223.
19. Kramer M, Winokur A, Kelsey J, Preskorn S, et al. (2004). Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29, 385-392.
20. Kramer MS, Cutler N, Feighner J, Shrivastava R, et al. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640-1645.
21. Lammertsma A, Hume S (1996). Simplified reference tissue model for PET receptor studies. NeuroImage 4, 153-158.
22. Liot PJ, Nemeroff CB, Kilts CD (1986). Evidence for a tonic facilitatory influence of substance P on dopamine release in the nucleus accumbens. Brain Research 385, 379-382.
23. Lipman RS (1982). Differentiating anxiety and depression in anxiety disorders : use of rating scales. Psychopharmacology Bulletin 18, 69-77.
24. Mathew SJ, Vythilingam M, Murrough JW, Zarate CA, et al. (2011). A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized,double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacoogy 21, 221-229.
25. Otsuka M, Yoshioka K (1993). Neurotransmitter functions of mammalian tachykinins. Physiological Reviews 73, 229-308.
26. Otsuka M, Yoshioka K, Yanagisawa M, Suzuki H, et al. (1995). Use of NK-1 receptor antagonists in the exploration of physiological functions of substance P and neurokinin A. Canadian Journal of Physiology and Pharmacology 73, 903-907.
27. Raskin A, Schulterbrandt J, Reatig N, McKeon JJ (1969). Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. Journal of Nervous and Mental Disease 148, 87-98.
28. Rupniak NM (2002). Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Current Opinion in Investigational Drugs 3, 257-261.
29. Solin O, Eskola O, Hamill TG, Bergman J, et al. (2004). Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation : ([18F]SPA-RQ). Molecular Imaging and Biology 6, 373-384.
30. Tattersall FD, Rycroft W, Cumberbatch M, Mason G, et al. (2000). The novel NK1 receptor antagonist MK-0869(L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39, 652-663.
31. Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, et al. (2010). Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology 20, 80-87.
32. Weisberg RB (2009). Overview of generalized anxiety disorder : epidemiology,presentation, and course. Journal of Clinical Psychiatry 70 (Suppl. 2), 4-9.
33. Zigmond AS, Snaith RP (1983).The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 67, 361-370.